Haloperidol | Haldol | CAS#52-86-8 | Antipsychotic

MedKoo Cat#: 317987 | Name: Haloperidol

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Haloperidol, marketed under the trade name Haldol, is a typical antipsychotic medication. It is used in the treatment of schizophrenia, tics in Tourette syndrome, nausea and vomiting, delirium, agitation, acute psychosis, and hallucinations in alcohol withdrawal. It may be used by mouth, as an injection into a muscle, or intravenously. Haloperidol typically works within thirty to sixty minutes. A long-acting formulation may be used as an injection every four weeks in people with schizophrenia or related illnesses who either forget or refuse to take the medication by mouth.

Chemical Structure

Haloperidol

CAS#52-86-8

Theoretical Analysis

MedKoo Cat#: 317987

Name: Haloperidol

CAS#: 52-86-8

Chemical Formula: C21H23ClFNO2

Exact Mass: 375.1401

Molecular Weight: 375.86

Elemental Analysis: C, 67.11; H, 6.17; Cl, 9.43; F, 5.05; N, 3.73; O, 8.51

Price and Availability

Size	Price	Availability
2g	USD 250.00	2 Weeks
5g	USD 500.00	2 Weeks
10g	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

R-1625; R 1625; R1625; Haloperidol; Haldol; Eukystol; Serenace; Aloperidin; Aloperidol; McN-JR 1625; McN-JR1625; McN-JR-1625; NSC 170973; NSC170973; NSC-170973; NSC 615296; NSC615296; NSC-615296;

IUPAC/Chemical Name

4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one

InChi Key

LNEPOXFFQSENCJ-UHFFFAOYSA-N

InChi Code

InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2

SMILES Code

C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F

Appearance

White to light yellow crystalline powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 375.86 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Fragoso VM, Hoppe LY, Araújo-Jorge TC, Azevedo MJ, Campos JD, Cortez CM, Oliveira GM. Use of haloperidol and risperidone in highly aggressive Swiss Webster mice by applying the model of spontaneous aggression (MSA). Behav Brain Res. 2016 Mar 15;301:110-8. doi: 10.1016/j.bbr.2015.12.010. Epub 2015 Dec 14. PubMed PMID: 26698401. 2: Al-Qadheeb NS, Skrobik Y, Schumaker G, Pacheco MN, Roberts RJ, Ruthazer RR, Devlin JW. Preventing ICU Subsyndromal Delirium Conversion to Delirium With Low-Dose IV Haloperidol: A Double-Blind, Placebo-Controlled Pilot Study. Crit Care Med. 2016 Mar;44(3):583-91. doi: 10.1097/CCM.0000000000001411. PubMed PMID: 26540397; PubMed Central PMCID: PMC4779647. 3: Palasz A, Rojczyk E, Golyszny M, Filipczyk L, Worthington JJ, Wiaderkiewicz R. Long-term treatment with haloperidol affects neuropeptide S and NPSR mRNA levels in the rat brain. Acta Neuropsychiatr. 2016 Apr;28(2):110-6. doi: 10.1017/neu.2015.56. Epub 2015 Oct 15. PubMed PMID: 26467816. 4: Carrasco G, Baeza N, Cabré L, Portillo E, Gimeno G, Manzanedo D, Calizaya M. Dexmedetomidine for the Treatment of Hyperactive Delirium Refractory to Haloperidol in Nonintubated ICU Patients: A Nonrandomized Controlled Trial. Crit Care Med. 2016 Feb 29. [Epub ahead of print] PubMed PMID: 26925523. 5: Dold M, Tardy M, Samara MT, Li C, Kasper S, Leucht S. Are all first-generation antipsychotics equally effective in treating schizophrenia? A meta-analysis of randomised, haloperidol-controlled trials. World J Biol Psychiatry. 2016 Feb 26:1-11. [Epub ahead of print] PubMed PMID: 26919194. 6: Yamamoto S, Ohta N, Matsumoto A, Horiguchi Y, Koide M, Fujino Y. Haloperidol Suppresses NF-kappaB to Inhibit Lipopolysaccharide-Induced Pro-Inflammatory Response in RAW 264 Cells. Med Sci Monit. 2016 Feb 4;22:367-72. PubMed PMID: 26842661; PubMed Central PMCID: PMC4747317. 7: Shen AN, Newland MC. Examination of clozapine and haloperidol in improving ketamine-induced deficits in an incremental repeated acquisition procedure in BALB/c mice. Psychopharmacology (Berl). 2016 Feb;233(3):485-98. doi: 10.1007/s00213-015-4120-x. Epub 2015 Oct 29. PubMed PMID: 26514554. 8: Gawlik-Kotelnicka O, Mielicki W, Rabe-Jabłońska J, Lazarek J, Strzelecki D. Impact of lithium alone or in combination with haloperidol on oxidative stress parameters and cell viability in SH-SY5Y cell culture. Acta Neuropsychiatr. 2016 Feb;28(1):38-44. doi: 10.1017/neu.2015.47. Epub 2015 Aug 19. PubMed PMID: 26286703. 9: Thomas T, Fang Y, Yuriev E, Chalmers DK. Ligand Binding Pathways of Clozapine and Haloperidol in the Dopamine D2 and D3 Receptors. J Chem Inf Model. 2016 Feb 22;56(2):308-21. doi: 10.1021/acs.jcim.5b00457. Epub 2016 Feb 2. PubMed PMID: 26690887. 10: Schubert KO, Föcking M, Wynne K, Cotter DR. Proteome and pathway effects of chronic haloperidol treatment in mouse hippocampus. Proteomics. 2016 Feb;16(3):532-8. doi: 10.1002/pmic.201500242. Epub 2016 Jan 13. PubMed PMID: 26607048. 11: Correa M, Pardo M, Bayarri P, López-Cruz L, San Miguel N, Valverde O, Ledent C, Salamone JD. Choosing voluntary exercise over sucrose consumption depends upon dopamine transmission: effects of haloperidol in wild type and adenosine A2AKO mice. Psychopharmacology (Berl). 2016 Feb;233(3):393-404. doi: 10.1007/s00213-015-4127-3. Epub 2015 Nov 10. PubMed PMID: 26554387. 12: Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84. doi: 10.1007/s00228-015-1965-1. Epub 2015 Oct 30. PubMed PMID: 26514968. 13: Brettner F, Janitza S, Prüll K, Weninger E, Mansmann U, Küchenhoff H, Jovanovic A, Pollwein B, Chappell D, Zwissler B, von Dossow V. Gender-Specific Differences in Low-Dose Haloperidol Response for Prevention of Postoperative Nausea and Vomiting: A Register-Based Cohort Study. PLoS One. 2016 Jan 11;11(1):e0146746. doi: 10.1371/journal.pone.0146746. eCollection 2016. PubMed PMID: 26751066; PubMed Central PMCID: PMC4713839. 14: Vandael E, Vandenberk B, Vandenberghe J, Spriet I, Willems R, Foulon V. Risk management of QTc-prolongation in patients receiving haloperidol: an epidemiological study in a University hospital in Belgium. Int J Clin Pharm. 2016 Jan 9. [Epub ahead of print] PubMed PMID: 26749342. 15: Datta S, Jamwal S, Deshmukh R, Kumar P. Beneficial effects of lycopene against haloperidol induced orofacial dyskinesia in rats: Possible neurotransmitters and neuroinflammation modulation. Eur J Pharmacol. 2016 Jan 15;771:229-35. doi: 10.1016/j.ejphar.2015.12.032. Epub 2015 Dec 19. PubMed PMID: 26712377. 16: Schrijver EJ, de Graaf K, de Vries OJ, Maier AB, Nanayakkara PW. Efficacy and safety of haloperidol for in-hospital delirium prevention and treatment: A systematic review of current evidence. Eur J Intern Med. 2016 Jan;27:14-23. doi: 10.1016/j.ejim.2015.10.012. Epub 2015 Nov 6. Review. PubMed PMID: 26553001. 17: Witten L, Bastlund JF, Glenthøj BY, Bundgaard C, Steiniger-Brach B, Mørk A, Oranje B. Comparing Pharmacological Modulation of Sensory Gating in Healthy Humans and Rats: The Effects of Reboxetine and Haloperidol. Neuropsychopharmacology. 2016 Jan;41(2):638-45. doi: 10.1038/npp.2015.194. Epub 2015 Jul 1. PubMed PMID: 26129678. 18: Manchia M, Pinna M, Carpiniello B. Haloperidol and loss of gray matter in schizophrenia: Reconciling meta-analytical results with molecular pharmacology. Psychiatry Res. 2016 Jan 30;235:209-10. doi: 10.1016/j.psychres.2015.12.010. Epub 2015 Dec 19. PubMed PMID: 26724909. 19: Slawson MH, Johnson-Davis KL. Quantitation of Haloperidol, Fluphenazine, Perphenazine, and Thiothixene in Serum or Plasma Using Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). Methods Mol Biol. 2016;1383:49-57. doi: 10.1007/978-1-4939-3252-8_6. PubMed PMID: 26660173. 20: An HM, Tan YL, Shi J, Wang ZR, Li J, Wang YC, Lv MH, Zhou DF, Soares JC, Kosten TR, Yang FD, Zhang XY. Beneficial effects of EGb761 and vitamin E on haloperidol-induced vacuous chewing movements in rats: Possible involvement of S100B mechanisms. Behav Brain Res. 2016 Jan 15;297:124-30. doi: 10.1016/j.bbr.2015.10.004. Epub 2015 Oct 9. PubMed PMID: 26455874.